HAIFA, Israel--(BUSINESS WIRE)--Jan. 12, 2006--Pluristem Life Systems, Inc. (OTC BB:PLRS), a biotechnology company dedicated to the commercialization of cell therapy products, today announced that the Company has formulated a cell graft to provide an efficient alternative to the standard procedure of bone marrow transplantation (BMT). The cell graft is presently in preclinical trials. The development of this new advanced engineered graft that replenishes the bone marrow of blood cancer patients can save the lives of million of people.
